DUBLIN--(BUSINESS WIRE)--Nov 25, 2021--

The "US Veterinary Oncology Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The U.S. veterinary oncology market size is expected to reach USD 143.2 million by 2028 and is expected to expand at a CAGR of 8.4% from 2021 to 2028.

The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canine as a model for clinical trials by researchers are the key contributing factor towards this segment growth. In addition, an increase in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth.

Moreover, companies operating in the market are increasingly adopting strategies, such as mergers and acquisitions, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their position in the market. For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline.

The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC. The drug also had received U.S. FDA approval for treating lymphoma in dogs. Hence, the market is expected to witness intense competition over the forecast period.

Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth. For instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected.

With the growing number of pet parents in the U.S., animal health awareness is rising amongst people. In the U.S. there are various pet health awareness events such as National Pet Week are conducted to create awareness.

The risk of animals spreading COVID-19 to individuals is considered to be little. The FDA is alert that the COVID-19 pandemic may influence ongoing studies being conducted to provision new animal drug development. Thereby, issued guidelines in April 2020 to help to diminish the potential impact of the pandemic on new animal drug development.

U.S. Veterinary Oncology Market Report Highlights

  • The radiology segment is expected to dominate the market. Factors such as increasing government initiatives to the establishment of new veterinary radiation centers and advancements in radiation technology are expected to boost demand for the radiation therapy segment
  • The immunotherapy segment is expected to witness a CAGR of 8.9% owing to the growing number of veterinary centers focused on carrying out clinical trials in immunotherapy areas
  • The chemotherapy segment is the second-largest segment of the market. According to Cancer Veterinary Center, the most common canine and feline tumors treated with chemotherapy are osteosarcomas, lymphomas, hemangiosarcoma, mast cell tumors, bladder tumors, and mammary gland tumors
  • The canine segment emerged as the largest revenue-generating segment of the market in 2020. The rising incidence of cancer in canines and ongoing product innovations in this domain is the key growth contributors

Key Topics Covered:

Chapter 1 Research Methodology & Scope

Chapter 2 Executive Summary

2.1 Market Outlook

2.2 U.S. Veterinary Oncology Market Summary, 2020

2.3 Segment Outlook

Chapter 3 Veterinary Oncology Market Variables Trends & Scope

3.1 Market Lineage Outlook

3.2 Penetration & Growth Prospect Mapping by Technology, 2020

3.3 U.S. Veterinary Oncology Market Dynamics

3.4 Industry Analysis - Porter's

3.5 U.S. Veterinary Oncology - SWOT Analysis, by Factor (Political & Legal, Economic, Social and Technological)

3.6 User Perspective Analysis

3.7 Regulatory Framework

3.8 Technology Overview

3.9 Product Pipeline Analysis

3.10 Pricing Trend Analysis

Chapter 4 COVID-19 Impact

4.1 COVID-19 Prevalence

4.2 Impact of COVID-19 on the Market

4.3 Regulatory/Policy Changes

4.4 Strategies Adopted by Market Players

Chapter 5 Competitive Analysis

5.1 Market Participation Categorization

5.2 Competitive Analysis

5.3 Market Entry Strategies

Chapter 6 U.S. Veterinary Oncology Market: Therapy Estimates & Trend Analysis

6.1 Therapy Market Share Analysis, 2020 & 2028

6.2 Therapy Dashboard

6.3 Surgery

6.4 Radiology

6.5 Chemotherapy

6.6 Immunotherapy

6.7 Others

Chapter 7 U.S. Veterinary Oncology Market: Animal Type Estimates & Trend Analysis

7.1 Animal Type Market Share Analysis, 2020 & 2028

7.2 Animal Type Dashboard

7.3 Canine

7.4 Feline

7.5 Others

Chapter 8 Company Profiles

8.1 Zoetis

8.2 Boehringer Ingelheim GmbH

8.3 Elanco

8.4 PetCure Oncology

8.5 Accuray Incorporated

8.6 Varian Medical Systems, Inc.

8.7 Morphogenesis, Inc.

8.8 Karyopharm Therapeutics, Inc.

8.9 Regeneus Ltd.

8.10 OHC (One Health Company)

8.11 List of Market Participants

For more information about this report visit https://www.researchandmarkets.com/r/ruh09c

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 11/25/2021 05:28 AM/DISC: 11/25/2021 05:28 AM

Copyright Business Wire 2021.

Recommended for you

(0) comments

Welcome to the discussion.

Real Names required. No pseudonyms or partial names allowed. Stand behind what you post.
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.

Thank you for reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.